Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)
Non-interventional Observational Study on the Influence of Pramipexole (PPX) on Sensory Symptoms of Restless Legs Syndrome (RLS)
Sponsor: Boehringer Ingelheim
This observational or N/A phase trial investigates Restless Legs Syndrome and is currently completed. Boehringer Ingelheim leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen, Germany , Achim, Germany , Ahrensburg, Germany , Albstadt, Germany , Alfeld, Germany , Allendorf, Germany , Alzenau in Unterfranken, Germany , Anklam, Germany , Annaberg-Buchholz, Germany , Ansbach, Germany and 470 more locations